RT Journal Article SR Electronic T1 Biodistribution and Radiation Dosimetry in Humans of a New PET Ligand, 18F-PBR06, to Image Translocator Protein (18 kDa) JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 145 OP 149 DO 10.2967/jnumed.109.068064 VO 51 IS 1 A1 Yota Fujimura A1 Yasuyuki Kimura A1 Fabrice G. Siméon A1 Leah P. Dickstein A1 Victor W. Pike A1 Robert B. Innis A1 Masahiro Fujita YR 2010 UL http://jnm.snmjournals.org/content/51/1/145.abstract AB As a PET biomarker for inflammation, translocator protein (18 kDa) (TSPO) can be measured with an 18F-labeled aryloxyanilide, 18F-N-fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline (18F-PBR06), in the human brain. The objective of this study was to estimate the radiation absorbed doses of 18F-PBR06 based on biodistribution data in humans. Methods: After the injection of 18F-PBR06, images were acquired from head to thigh in 7 healthy humans. Urine was collected at various time points. Radiation absorbed doses were estimated by the MIRD scheme. Results: Moderate to high levels of radioactivity were observed in organs with high densities of TSPO and in organs of metabolism and excretion. Bone had low levels of radioactivity. The effective dose was 18.5 μSv/MBq. Conclusion: The effective dose of 18F-PBR06, compared with other 18F radioligands, was moderate. This radioligand had negligible defluorination, as indirectly assessed by bone radioactivity. Doses to the gallbladder wall and spleen may limit the amount of permissible injected radioactivity.